Jerry Durso has more than 30 years of experience building and leading commercial and business operations across the life sciences industry in the United States and abroad. He is a commercial-stage public company executive with a long track record of success at the intersection of strategy and operations, driving growth across diverse business models and therapeutic areas including rare disease, specialty, hospital, and mass market products.
Mr. Durso most recently served as Chief Executive Officer and a member of the Board of Directors of Intercept Pharmaceuticals, a company focused on liver diseases, where he built a successful rare disease franchise, transformed the corporate strategy, and ultimately led the company through its successful acquisition by Alfasigma. Prior to becoming CEO, he served as Intercept’s Chief Operating Officer from 2017 to 2021.
Before Intercept, Mr. Durso spent over two decades at Sanofi, a global pharmaceutical company, where he oversaw multiple blockbuster franchises while holding senior leadership positions including Chief Commercial Officer of Sanofi’s Global Diabetes Division and Chief Commercial Officer of its U.S. Pharmaceuticals business.
Mr. Durso joined the Board of Directors of Altimmune in February 2025 and was named Chairman of the Board in August 2025. He assumed the role of President and Chief Executive Officer in January 2026.
Mr. Durso earned his BBA in Marketing from the University of Notre Dame.
What is Jerome Benedict Durso's net worth?
The estimated net worth of Jerome Benedict Durso is at least $110.83 thousand as of March 6th, 2026. Mr. Durso owns 32,500 shares of Altimmune stock worth more than $110,825 as of April 21st. This net worth estimate does not reflect any other investments that Mr. Durso may own. Learn More about Jerome Benedict Durso's net worth.
How do I contact Jerome Benedict Durso?
Has Jerome Benedict Durso been buying or selling shares of Altimmune?
Jerome Benedict Durso has not been actively trading shares of Altimmune during the past quarter. Most recently, on Friday, March 6th, Jerome Benedict Durso bought 20,000 shares of Altimmune stock. The stock was acquired at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the transaction, the chief executive officer now directly owns 32,500 shares of the company's stock, valued at $115,050. Learn More on Jerome Benedict Durso's trading history.
Who are Altimmune's active insiders?
Are insiders buying or selling shares of Altimmune?
During the last twelve months, Altimmune insiders bought shares 6 times. They purchased a total of 55,527 shares worth more than $213,777.60. The most recent insider tranaction occured on March, 6th when CFO Gregory L Weaver bought 5,000 shares worth more than $17,700.00. Insiders at Altimmune own 1.6% of the company.
Learn More about insider trades at Altimmune. Information on this page was last updated on 3/6/2026.
